Abstract: A nanochannel delivery device and method of manufacturing and use. The nanochannel delivery device comprises an inlet, an outlet, and a nanochannel. The nanochannel may be oriented parallel to the primary plane of the nanochannel delivery device. The inlet and outlet may be in direct fluid communication with the nanochannel.

Abstract: Disclosed are methods and compositions containing functionalized nanoporous silicon particles, useful in a variety of diagnostic and/or therapeutic regimens for delivery of genetic constructs to one or more cells, tissues, and/or organs of interest. Also provided are methods for introducing into selected host cells one or more selected nucleic acid molecules. The present disclosure is also directed to a method of treating a tumor, comprising the step of administering to an individual one or more of the compositions and formulations thereof as described herein.

Abstract: Multistage delivery vehicles are disclosed which include a first stage particle and a second stage particle. The first stage particle is a micro or nanoparticle that contains the second stage particle. The second stage particle includes an active agent, such as a therapeutic agent or an imaging agent. The multistage delivery vehicle allows sequential overcoming or bypassing of biological barriers. The multistage delivery vehicle is administered as a part of a composition that includes a plurality of the vehicles. Methods of making the multistage delivery vehicles are also provided.

Abstract: Provided is a particle that includes a first porous region and a second porous region that differs from the first porous region. Also provided is a particle that has a wet etched porous region and that does have a nucleation layer associated with wet etching. Methods of making porous particles are also provided.

Abstract: A method for detecting hepcidin. Having a sample liquid in contact with a nanochip having a specific surface coating structure of silicon oxide, so that hepcidin is enriched with specificity; eluting the nanochip with an eluent; by performing mass spectrometric detection on the elution product, determining the hepcidin content in the elution product. The enrichment method substantially enhances the sensitivity and accuracy of mass spectrometric detection. A kit for detecting hepcidin comprising a sample diluent and a nanochip, the sample diluent comprising water, trifluoroacetic acid, and acetonitrile.

Abstract: A capsule configured for in vivo refilling of a therapeutic agent. In certain embodiments, the capsule may contain methotrexate.

Abstract: An apparatus for slicing food products includes a container for the food product and a movable carriage carrying the container and product towards a cutting plane defined by a rotating blade. After slicing, the container can be removed from the carriage and then vacuum sealed for preserving the remaining unsliced product.

Abstract: A capsule configured for in vivo refilling of a therapeutic agent. In certain embodiments, the capsule may contain methotrexate.

Abstract: A nanochannel delivery device and method of manufacturing and use. The nanochannel delivery device comprises an inlet, an outlet, electrodes and a nanochannel. The nanochannel may be oriented parallel to the primary plane of the nanochannel delivery device. The inlet and outlet may be in direct fluid communication with the nanochannel.

Abstract: Disclosed are mesoporous silicon multi-stage vehicles that comprise liposomal-based second-stage particles, as well as pharmaceutical compositions and formulations including such vectors for use in a variety of diagnostic and therapeutic indications. In particular embodiments, MSV comprising ligand decorated second-stage particles are provided for therapeutic methods including, for example, treatment of mammalian cancers, including those of the human breast.

Abstract: Provided is a particle that includes a first porous region and a second porous region that differs from the first porous region. Also provided is a particle that has a wet etched porous region and that does have a nucleation layer associated with wet etching. Methods of making porous particles are also provided.

Abstract: Nanoporous materials can be used to enrich samples for subsequent analysis of substances contained in the sample. The method is shown to enrich the yield of species in the low molecular weight proteome, allowing detection of small peptides in the low nanomolar range.

Abstract: The present invention provides methods and compositions for the nanotechnology-based therapy of one or more mammalian diseases. Disclosed are gold-in-porous silicon nanoassemblies that are effective in the targeted and localized treatment of one or more human hyperproliferative disorders, including, for example, cancer of the breast. Methods of systemic administration of these nanoassembly vectors are disclosed that facilitate direct thermal ablative therapy of selected tissues using a localized application of near-infrared energy to the target site, wherein the gold-in-porous silicon nanoparticles release heat to destroy the surrounding cancerous tissue.

Abstract: A method for detecting hepcidin. Having a sample liquid in contact with a nanochip having a specific surface coating structure of silicon oxide, so that hepcidin is enriched with specificity; eluting the nanochip with an eluent; by performing mass spectrometric detection on the elution product, determining the hepcidin content in the elution product. The enrichment method substantially enhances the sensitivity and accuracy of mass spectrometric detection. A kit for detecting hepcidin comprising a sample diluent and a nanochip, the sample diluent comprising water, trifluoroacetic acid, and acetonitrile.

Abstract: A capsule configured for in vivo refilling of a therapeutic agent. In certain embodiments, the capsule may contain methotrexate.

Abstract: Nanoporous materials can be used to enrich samples for subsequent analysis of substances contained in the sample. The method is shown to enrich the yield of species in the low molecular weight proteome, allowing detection of small peptides in the low nanomolar range.

Abstract: A new fractionation device shows desirable features for exploratory screening and biomarker discovery. The constituent MSCs may be tailored for desired pore sizes and surface properties and for the sequestration and enrichment of extremely low abundant protein and peptides in desired ranges of the mass/charge spectrum. The MSCs are effective in yielding reproducible extracts from complex biological samples as small as 10 ?l in a time as short as 30 minutes. They are inexpensive to manufacture, and allow for scaled up production to attain the simultaneous processing of a large number of samples. The MSCs are multiplexed, label-free diagnostic tools with the potential of biological recognition moiety modification for enhanced specificity. The MSCs may store, protect and stabilize biological fluids, enabling the simplified and cost-effective collection and transportation of clinical samples.

Abstract: A capsule configured for in vivo refilling of a thereapeutic agent. In certain embodiments, the capsule may contain methotrexate.

Abstract: The present disclosure is directed to a composition for the sustained-release delivery of an active agent to a target cell of an individual. The compositions disclosed herein comprise of at least one porous particle; at least one polymer; and at least one active agent. In an embodiment, the porous particle comprises a plurality of microscale reservoirs. In an exemplary embodiment, the at least one active agent is covalently linked to the at least one polymer to form a polymer-active agent conjugate, and the polymer-active agent conjugate is contained in the plurality of microscale reservoirs of the porous particle. The present disclosure is also directed to a method of treating a tumor, comprising the step of administering to an individual the composition described supra. Additionally, disclosed herein is a method of eliminating tumor stem cells. Furthermore, there is provided a method of circumventing multi-drug resistance in a tumor cell.

Abstract: Disclosed are a variety of porous and non-porous wire-like structures of microscopic and nanoscopic scale. For instance, disclosed are structures that comprise a porous object that comprises: (i) a first region; and (ii) a second region adjacent to the first region along an axis of the object, where the first region has at least one porous property different from that of the second region. Also disclosed are structures that include: (i) a high resistivity silicon; and (ii) a cross-section that is substantially perpendicular to an axis of the object. Also disclosed are methods of making and using such structures.